The Blood-Brain/Tumor Barriers: Challenges and Chances for Malignant Gliomas Targeted Drug Delivery

Author(s): Changyou Zhan, Weiyue Lu

Journal Name: Current Pharmaceutical Biotechnology

Volume 13 , Issue 12 , 2012

Become EABM
Become Reviewer
Call for Editor


Treatment of malignant gliomas remains a challenge irrespective of the recent improvements. Chemotherapeutic agents for malignant gliomas have been particularly inefficient for the existence of blood-tumor barrier (BTB), which hampers the accumulation and uptake in tumor. Moreover, even though blood-brain barrier (BBB) is compromised to some extent under the situation of malignant gliomas, it remains to be the obstacle influencing the therapeutic efficacies via systemic administration. Fortunately, there are many receptors over-expressed on the BTB (glioma cells and/or tumor microvessels) that can mediate ligand modified drug delivery systems targeting to gliomas and enhance tumor uptake. On the other hand, numerous routes have also been explored to circumvent the BBB. In this manuscript, we elucidate the BBB/BTB status under the situation of malignant gliomas and review the receptors over-expressed on BTB and the malignant gliomas targeted drug delivery strategies. We also discuss the perspective of malignant gliomas targeted drug delivery systems with new concepts.

Keywords: Gliomas, blood-brain barrier, blood-tumor barrier, targeted drug delivery system, therapy, Treatment of malignant gliomas, Chemotherapeutic agents for malignant, tumor, tumor microvessels, glioma cells, glioblastoma multiforme, median survival, glioma, chemotherapeutic efficacies

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2012
Published on: 05 October, 2012
Page: [2380 - 2387]
Pages: 8
DOI: 10.2174/138920112803341798
Price: $65

Article Metrics

PDF: 43